ClinicalTrials.gg
Active, not recruitingNCT04396002Updated Oct 27, 2026

Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

An observational study in Primary Open Angle Glaucoma, sponsored by University of Alabama at Birmingham. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of Alabama at Birmingham · Observational

How we know

Updated Oct 27, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Planned enrollment
25th of 57
100 · median 100
Started
2019
with 15 others
Observational
59 of 348
13 open now
Primary completion
2027-05
later than 32 of 66 live
Registered
230th of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 25th largest by planned enrollment of the 57 observational ones that give a count, is one of 16 that started in 2019, is one of 59 observational ones, reaches primary completion later than 32 of the 66 other live ones, and was the 230th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on the other extreme. Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy that can lead to gradual loss of vision in the peripheral field and central vision. Older adults with POAG have an increased risk for motor vehicle collisions and falls. Moreover, existing studies suggest that patients with POAG exhibit more postural sway while standing as measured by a balance platform and also tend to walk more slowly than those who are normally sighted and free of ocular disease. While these disturbances likely influence mobility, there has been little research directly assessing the impact of POAG on mobility. This study will assess the impact of POAG on life space (one aspect of mobility) and will determine whether difficulties with life space are associated with difficulties experienced under conditions of dim lighting.

Read the detailed description

Aim 1: To determine whether differences exist between people with healthy eyes and patients with POAG in seeing under dim illumination (Low Luminance Questionnaire) and to determine whether such differences are associated with life space.

Aim 2: To determine whether differences exist between people with healthy eyes and patients with POAG in seeing under dim illumination (objective measures of visual function) and to determine whether such differences are associated with life space.

03

Conditions studied

  • Primary Open Angle Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients:

Participants that are enrolled in the Early Detection of Glaucoma Progression using a Novel Individualized Approach (IRB-300000301) or in the African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the Lamina Cribrosa in Progression (IRB-161115004).

Controls:

Participants with healthy eyes will be recruited.

Eligibility criteria

Inclusion Criteria (Patients):

  • Participants that are enrolled in the Early Detection of Glaucoma Progression using a Novel Individualized Approach (IRB-300000301) or in the African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the Lamina Cribrosa in Progression (IRB-161115004).

Exclusion Criteria (Patients):

  • Not being enrolled in one of the following two NIH-funded studies: 1. African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the lamina cribrosa in progression (EY026574) or 2. Early detection of glaucoma progression using a novel individualized approach (EY025756)

Inclusion Criteria (Controls):

  • No diagnosis of eye disease

Exclusion Criteria (Controls):

  • Cognitive impairment that would preclude ability to take the tests
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Primary Open-Angle Glaucoma

    Patients diagnosed with primary open-angle glaucoma.

    Diagnostic Test: Life Space Questionnaire · Diagnostic Test: Low Luminance Questionnaire · Diagnostic Test: Contrast sensitivity under dim illumination · Diagnostic Test: Visual field under dim illumination (MAIA) · Diagnostic Test: Macular Pigment Optical Density (MPOD) · Diagnostic Test: Dark Adaptation

  • Control

    Participants with healthy eyes.

    Diagnostic Test: Life Space Questionnaire · Diagnostic Test: Low Luminance Questionnaire · Diagnostic Test: Contrast sensitivity under dim illumination · Diagnostic Test: Visual field under dim illumination (MAIA) · Diagnostic Test: Macular Pigment Optical Density (MPOD) · Diagnostic Test: Dark Adaptation

Interventions

  • Diagnostic testLife Space Questionnaire

    This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.

  • Diagnostic testLow Luminance Questionnaire

    This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions.

  • Diagnostic testContrast sensitivity under dim illumination

    Participants will be presented with visual targets of different contrast under dim illumination and asked to report when they see the target.

  • Diagnostic testVisual field under dim illumination (MAIA)

    Sensitivity in the central visual area will be assessed under dim illumination

  • Diagnostic testMacular Pigment Optical Density (MPOD)

    Participants will be asked to look at a fixation target and the density of their macular pigment will be assessed.

  • Diagnostic testDark Adaptation

    After adapting to a dark environment, participants will be exposed a bright flask of light. the time needed for them to recover their sensitivity will be measured.

06

What researchers measure

Primary outcomes

  1. Assessment of life space measured with the Life Space Questionnaire

    The Life Space Questionnaire is a 9-item questionnaire that assesses how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame. Patients are asked to respond either Yes or No.

    Time frame: Through study completion, an average of 1 year

  2. Assessment of vision under low luminance conditions

    The Low Luminance Questionnaire is a 32-item questionnaire that assesses how participants see under dim illumination and how well they can perform different tasks (e.g. reading, driving). Patients are asked to select a response among different choices on a Likert scale that ranges from 1 to 5, 1 to 6, 1 to 7, or 1 to 8 depending on the question. A response of "1" indicates that the participant experiences no difficulty while increasingly higher numbers indicate increasing amounts of difficulty.

    Time frame: Through study completion, an average of 1 year

  3. Differences in contrast sensitivity functions between controls and patients

    Participants will be presented with targets of different spatial frequency at different contrasts. Their sensitivity at each spatial frequency will be recorded/

    Time frame: Through study completion, an average of 1 year

  4. Differences in dark adaptation between controls and patients

    Once participants have adapted to a dark environment, they will be exposed to a bright flash of light. The time needed to recover their visual sensitivity will be measured (rod-intercept time).

    Time frame: Through study completion, an average of 1 year

  5. Differences in visual sensitivity under dim illumination between controls and patients

    Participants will be presented with targets at different locations in their visual fields under dim illumination.

    Time frame: Through study completion, an average of 1 year

  6. Differences in Macular Pigment Optical Density between controls and patients

    Participants will fixate on a target while their MPOD is assessed. The MPOD is measured using the Heidelberg optical coherence tomography (OCT) MPOD module. Two different light sources are directed to the back of the eye. The light is reflected back and the OCT/MPOD computes the difference in the reflectance of the two lights which is an estimate of the density of macular pigment.

    Time frame: Through study completion, an average of 1 year

  7. Assessment of the relationship between each the measure of visual function and life space

    The relationship between each of the measures of visual function (dark adaptation, contrast sensitivity functions, visual fields under dim illumination, and MPOD) and life space (Life Space Questionnaire will be assessed.

    Time frame: Through study completion, an average of 1 year

  8. Assessment of the relationship between each the measure of visual function and self-reported visual function under dim illumination

    The relationship between each of the measures of visual function (dark adaptation, contrast sensitivity functions, visual fields under dim illumination, and MPOD) and self-reported visual performance under dim illumination (Low Luminance Questionnaire) will be assessed.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2019 (actual). Primary completion is estimated for May 2027, 95 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion May 2026 → May 2027 and completion May 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2020
First posted
May 20, 2020
StartActual
Jun 1, 2019
Primary completionEst.
May 30, 2027was May 2026
CompletionEst.
May 30, 2027was May 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 27, 2026
Primary completion
May 30, 2026→May 30, 2027
Oct 27, 2026
Study completion
May 30, 2026→May 30, 2027
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Active, not recruiting
    Primary completion May 30, 2026→May 30, 2027
    Study completion May 30, 2026→May 30, 2027
    + 4 other changes: verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04396002
Responsible party
Lyne Racette (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
May 20, 2020
Start date
Jun 1, 2019
Primary completion
May 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Lyne Racette, PhD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion